Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
Orchestra BioMed Holdings director and officer Darren Sherman sold 15,000 shares of common stock in an open-market sale. The transaction occurred at a weighted average price of about $4.27 per share, with individual sale prices ranging from $4.21 to $4.32.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. After this transaction, Sherman directly holds 1,169,327 shares, indicating he retains a substantial continuing stake in Orchestra BioMed.
Darren Sherman filed a Form 144 to sell common stock. The notice lists a proposed sale of 15,000 shares reported with a sale date of 06/01/2026 and a gross amount of $58,049.53. The filing also lists restricted stock vesting events of 9,292 and 5,708 shares on 09/09/2024 and 11/25/2024, respectively.
Orchestra BioMed Holdings director compensation and tax withholding activity was reported through the Fain Living Trust. On June 23, 2026, the trust received 17,327 shares of Common Stock as a grant of restricted stock units, each representing one future share subject to service-based vesting after one year.
On the same date, the trust was granted 21,277 stock options with an exercise price of $4.04 per share, expiring on June 23, 2036, which also vest after one year of continuous service. On June 24, 2026, 4,261 shares were withheld by the issuer to cover tax obligations upon RSU vesting, with no market sale of shares. Following these transactions, the trust held 104,775 shares of Common Stock indirectly for the reporting person.
Orchestra BioMed Holdings director David Pacitti reported compensation-related equity awards and a routine tax withholding. On June 23, 2026, he received 17,327 restricted stock units, each representing one future share of common stock, and a stock option for 21,277 shares at an exercise price of $4.04 per share. Both the RSUs and options vest on the one-year anniversary of the grant date, contingent on his continued service. On June 24, 2026, 3,784 shares were withheld by the company to cover tax obligations upon RSU vesting, with no shares sold in the market. Following these transactions, he directly holds 58,511 common shares and holds options for 21,277 additional shares.
Orchestra BioMed Holdings director Chris Cleary reported compensation-related equity transactions. On this Form 4, 3,510 shares of common stock were disposed of through share withholding to cover tax obligations tied to vesting of restricted stock units, and no shares were sold in the market. After this tax-withholding disposition, Cleary directly holds 33,391 common shares.
He also received a grant of stock options for 42,553 shares of common stock at an exercise price of $4.04 per share, expiring on June 23, 2036. According to the footnote, these options will vest on the one-year anniversary of June 23, 2026, subject to his continuous service with the company.
Orchestra BioMed Holdings, Inc. director Pamela Ann Connealy received equity compensation in the form of restricted stock units and stock options. She was granted 17,327 RSUs, each representing one future share of Common Stock, which vest on the one-year anniversary of the June 23, 2026 grant date, subject to continued service.
She also received stock options for 21,277 shares of Common Stock at an exercise price of $4.0400 per share, expiring on June 23, 2036, which vest on the same one-year schedule. Following the RSU award, her direct Common Stock holdings total 66,038 shares.
Orchestra BioMed Holdings director Aryeh Jason received a new stock option grant. The award covers 42,553 options to buy Common Stock at an exercise price of $4.04 per share, with no cash paid at grant.
The options were granted on June 23, 2026 and will vest on the one-year anniversary of the June 23, 2026 grant date, as long as Jason continues to serve the company through that date. After this award, he holds 42,553 options directly, and there were no share sales or open-market purchases reported in this filing.
Orchestra BioMed Holdings, Inc. director John Prosper Mack reported routine equity compensation activity involving restricted stock units (RSUs). On the grant date, he received 34,653 RSUs, each representing one future share of common stock, vesting after one year of continued service.
When previously granted RSUs vested, 3,510 shares were withheld by the company to cover tax obligations, with no shares sold in the market. Following these transactions, he holds 71,429 shares of common stock directly.
Orchestra BioMed Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 59,880,715 common shares entitled to vote as of April 28, 2026, 49,053,298 shares were represented, allowing stockholders to act on five proposals.
Stockholders elected three Class III directors, David P. Hochman, Darren R. Sherman, and Eric S. Fain, to serve until the 2029 annual meeting. They ratified Ernst & Young LLP as independent auditor for 2026, approved the 2026 equity incentive plan, and supported, on an advisory basis, the compensation of named executive officers. In an advisory vote on frequency of future say‑on‑pay votes, stockholders indicated a preference for holding this vote every one year, which the company intends to follow until the next required frequency vote, expected in 2032.
Orchestra BioMed Holdings, Inc. Chief Financial Officer Andrew Taylor Lawrence reported a tax-related share withholding linked to restricted stock unit vesting. The issuer withheld 36,352 shares of common stock at an implied value of $4.02 per share to satisfy tax withholding obligations, and no shares were sold in the market. After this withholding, Lawrence directly holds 593,065 shares of Orchestra BioMed common stock.